Pacific Biosciences, GenDx initiate co-marketing activities for full-length HLA Pacific Biosciences and GenDx announced a co-marketing agreement to offer products for full-length HLA gene sequencing. GenDx, which currently offers reagents for the amplification of full-length, Class I HLA genes, will offer a version of its NGSgo reagent line with barcoded primers developed with Pacific Biosciences for sequencing on the PacBio RS II DNA sequencing system. Using the GenDx NGSengine software package to analyze data from the PacBio system provides customers with a highly accurate, allele-level HLA typing solution. This new reagent kit will allow the pooling of full-length, Class I HLA genes from multiple samples into a single sequencing run.
News For PACB From The Last 14 Days
Check below for free stories on PACB the last two weeks.
Pacific Biosciences milestone payment shows Roche commitment, says Maxim Maxim believes Roche's (RHHBY) milestone payment to Pacific Biosciences (PACB) indicates that the larger partner is committed to continuing the in vitro diagnostics program despite its recent acquisition and strategic investment with others. Maxim raised its 2014 revenue estimate for Pacific Biosciences to reflect the payment and recommends investors buy shares.